How Does Blenrep Work for Multiple Myeloma? Blenrep is an antibody-drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs contain two parts, a protein called an antibody and an ...
GSK on Monday said its drug Blenrep outperformed Johnson & Johnson’s Darzalex in a clinical trial of people with the blood cancer multiple myeloma, potentially cracking open the door to Blenrep’s ...
The European Medicines Agency (EMA) has accepted for review GSK’s marketing authorisation application (MAA) for Blenrep (belantamab mafodotin), an antibody-drug conjugate (ADC), to treat relapsed or ...
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep. Blenrep is approved for the treatment of adults with multiple myeloma in ...
Blenrep, combined with Velcade and dexamethasone, is approved for relapsed/refractory multiple myeloma after two prior therapies, showing significant survival benefits. The phase 3 DREAMM-7 trial ...
Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F. The Food and Drug Administration (FDA) ...
Two of my recent post topics (on antibody-drug conjugates and on accelerated approval) have intersected today. Median progression-free survival was actually better with Blenrep, but the main way to ...
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the ...
Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback